Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Phenex Pharmaceuticals
Biotech
Gilead 'strikes out' in NASH with phase 2 flop: analysts
Gilead's NASH prospects firsocotat and cilofexor failed to move the needle on liver scarring in a phase 2 study, on their own or in combination.
Amirah Al Idrus
Dec 16, 2019 11:01am
Gilead's FXR drug posts positive phase 2 data in liver condition
Nov 9, 2018 11:12am
Chutes & Ladders: Pfenex CEO resigns after in-house investigation
Jan 27, 2017 1:57pm